Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

75.0%

-11.6% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A

2(50.0%)

Phase 3

1(25.0%)

Phase 1

1(25.0%)

4Total

N/A(2)

Phase 3(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT04747054Phase 3Recruiting

Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers

Role: collaborator

NCT03401840Not ApplicableCompleted

STEREO-POSTOP 01 (PostOperative Hypofractionated Stereotactic Body Radiotherapy ) - GORTEC 2017-03

Role: collaborator

NCT04397575Completed

The GCO-002 CACOVID-19 Cohort: a French Nationwide Multicenter Study of COVID-19 Infected Cancer Patients

Role: collaborator

NCT01149642Not ApplicableCompleted

Randomised Study of Mucositis Prevention After Radiochemotherapy Treatment for Head and Neck Cancer

Role: collaborator

NCT03114280Phase 1Withdrawn

Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)

Role: collaborator

All 5 trials loaded